Literature DB >> 19000557

Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.

T Maiguma1, Y Hayashi, S Ueshima, H Kaji, T Egawa, K Chayama, T Morishima, Y Kitamura, T Sendo, Y Gomita, D Teshima.   

Abstract

OBJECTIVE: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim of this study was to evaluate the relationship between the MTX serum concentration and occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study.
METHODS: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m2 for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity of MTX for human epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC48h-inf) and elimination half-life (t1/2b) were done using the 1-compartmental models.
RESULTS: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group with a concentration under 10-6 M 48 h after MTX administration. There was no significant deference among the cell viabilities in the concentrations of 10-6 M, 10-5 M and 10-4 M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t1/2b (p = 0.025) and AUC48h- yen (p = 0.025) increased significantly compared with the non-symptom group.
CONCLUSIONS: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000557     DOI: 10.5414/cpp46584

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  9 in total

1.  Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.

Authors:  M A H den Hoed; E Lopez-Lopez; M L te Winkel; W Tissing; J D E de Rooij; A Gutierrez-Camino; A Garcia-Orad; E den Boer; R Pieters; S M F Pluijm; R de Jonge; M M van den Heuvel-Eibrink
Journal:  Pharmacogenomics J       Date:  2014-11-04       Impact factor: 3.550

2.  Use of Surrogate Samples to Monitor pH During High dose Methotrexate Therapy.

Authors:  Uday Yanamandra; Pooja Chauhan; Deepesh Lad; Alka Khadwal; Gaurav Prakash; Subhash Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-06       Impact factor: 0.900

3.  Low-level laser or LED photobiomodulation on oral mucositis in pediatric patients under high doses of methotrexate: prospective, randomized, controlled trial.

Authors:  Douglas Magno Guimaraes; Tamara Melo Nunes Ota; Diego Assunção Calixto Da Silva; Fabio De Lucas Da Silva Almeida; Tatiana Dias Schalch; Alessandro Melo Deana; Jose Miguel Alves Junior; Kristianne Porta Santos Fernandes
Journal:  Support Care Cancer       Date:  2021-04-24       Impact factor: 3.603

4.  Chemotherapy-induced oral mucositis in children and adolescents: a systematic review.

Authors:  R Docimo; M D Anastasio; C Bensi
Journal:  Eur Arch Paediatr Dent       Date:  2022-07-02

5.  The effect of Orem-based self-care education on improving self-care ability of patients undergoing chemotherapy: a randomized clinical trial.

Authors:  Tayebeh Rakhshani; Siamak Najafi; Fakhry Javady; Alireza Taghian Dasht Bozorg; Fatemeh Mohammadkhah; Ali Khani Jeihooni
Journal:  BMC Cancer       Date:  2022-07-15       Impact factor: 4.638

6.  Oral manifestations in the Graft versus Host Disease in paediatric patients: case report.

Authors:  P Maturo; R Condò; M Costacurta; R Docimo
Journal:  Oral Implantol (Rome)       Date:  2010-03-04

7.  Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy.

Authors:  Velia Ramírez-Amador; Gabriela Anaya-Saavedra; Erick Crespo-Solís; Esther Irigoyen Camacho; Imelda González-Ramírez; Sergio Ponce-de-León
Journal:  Support Care Cancer       Date:  2009-08-06       Impact factor: 3.603

8.  Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.

Authors:  Xiao Li; Zhongguo Sui; Fanbo Jing; Wen Xu; Xiangpeng Li; Qie Guo; Shuhong Sun; Xiaolin Bi
Journal:  Cancer Manag Res       Date:  2019-07-05       Impact factor: 3.989

9.  Effect of taxifolin on methotrexate-induced oxidative and inflammatory oral mucositis in rats: biochemical and histopathological evaluation.

Authors:  Zeynep Bayramoglu; Behzad Mokhtare; Ali Sefa Mendil; Taha Abdulkadir Coban; Renad Mammadov; Seval Bulut; Zeynep Suleyman; Halis Suleyman
Journal:  J Appl Oral Sci       Date:  2022-09-19       Impact factor: 3.144

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.